Hong Kong, China

HUTCHMED, a Hong Kong-based biopharmaceutical company, is on track to become a global leader in the discovery, development, and commercialisation of innovative, highly selective oral tyrosine kinase inhibitor therapies for oncology and immunological indications.

Investment Perspective

HUTCHMED has ambitious near- and medium-term growth plans, centred on its novel oncology products, to initially create a sizeable commercial organisation addressing Greater China whilst also building the appropriate infrastructure to address key global markets. The first product wave – Elunate (fruquintinib), Orpathys (savolitinib) and Sulanda (surufatinib) – are expected to post FY22 revenues of $160-$190m in China. The second and third waves of innovative programmes are progressing through development, with highly encouraging clinical profiles. This note details the status and relative importance of the key programmes and complements our September 2022 Outlook. Our valuation is $5.51bn/ £4.59bn/ HK$43.08bn, equivalent to $31.89/ADS or 531p/HK$49.83 per share.

Market information



FRESCO-2 data support broad uptake in later-line mCRC
Update | 21 Sep 2022
Rich and diverse pipeline with multiple waves of growth
Update | 06 Sep 2022
On the right track
Outlook | 01 Sep 2022

Recent News

FRESCO-2 data summary
08 Sep 2022
Fruquintinib FRESCO-2 data to be presented at ESMO
23 Aug 2022
First participant in IMG-004 Phase I trial
09 Aug 2022
SAVANNAH shows 49% ORR in high MET lung cancer
08 Aug 2022